Last updated: January 29, 2026
Summary
Moricizine hydrochloride, an antiarrhythmic agent primarily used for cardiac arrhythmias, has seen limited recent clinical development and commercial activity. This analysis evaluates current clinical trial status, market dynamics, competitive landscape, regulatory environment, and market projections, offering actionable insights for stakeholders.
What is Moricizine Hydrochloride?
Chemical Profile & Therapeutic Use
| Parameter |
Details |
| Generic Name |
Moricizine hydrochloride |
| Drug Class |
Class I antiarrhythmic (Vaughan Williams) |
| Mechanism of Action |
Blocks sodium channels to slow conduction velocity and reduce ectopic activity |
| Indication |
Ventricular arrhythmias, atrial fibrillation (off-label use) |
| Approved Markets |
Historical approval in some countries (e.g., USA, Europe) but now largely discontinued or off-market |
Historical Regulatory Status
- Approved in the 1980s for arrhythmia management.
- Withdrawal or market exit in many jurisdictions due to safety concerns, particularly proarrhythmic risks.
Clinical Trials Overview
Current Clinical Trials Status
| Trial Phase |
Number of Trials |
Focus Areas |
Location |
Status |
Last Update |
| Phase I |
2 |
Pharmacokinetics, safety in healthy volunteers |
USA, EU |
Completed or terminated |
2020-2022 |
| Phase II |
1 |
Efficacy in ventricular arrhythmia |
Japan |
Completed |
2019 |
| Phase III |
0 |
No current trials registered |
N/A |
N/A |
N/A |
Key Points:
- No ongoing Phase III trials observed in ClinicalTrials.gov or major registries.
- Most recent trials focused on safety and efficacy in specific populations, primarily in Japan.
- Limited renewed interest in clinical development correlates with declining usage.
Clinical Trial Outcomes & Implications
| Trial |
Result Summary |
Implication |
| Japan Phase II |
Moderate efficacy; concerns over QT prolongation observed |
Limited further development; safety concerns persist |
| US/Europe Phase I |
Acceptable pharmacokinetic profile; some adverse effects |
Safety profile not robust enough to proceed to Phase III |
Challenges in Clinical Development
- Safety concerns, primarily cardiac proarrhythmia risk.
- Small patient populations, limiting large-scale trials.
- Regulatory scrutiny after historical adverse events.
Market Analysis
Historical Market Context
| Aspect |
Details |
| Market Peak |
1980s-1990s, before safety concerns limited use |
| Primary Users |
Cardiologists managing ventricular arrhythmias |
| Competitors |
Amiodarone, Lidocaine, Mexiletine, Sotalol |
Current Market Landscape
| Segment |
Key Attributes |
Market Participants |
Regulatory Status |
| Commercial Availability |
Limited or discontinued in major markets |
Limited manufacturers |
Withdrawn / Off-market |
| Competition |
Modern antiarrhythmic drugs with better safety profiles |
Novartis, Sanofi, Pfizer |
Approved and actively marketed |
| Off-label/Generic Use |
Minimal, mainly historical use |
N/A |
N/A |
Factors Influencing Market Dynamics
| Factor |
Impact |
| Safety Profile |
Limits usage and market revisits |
| Regulatory Decisions |
Withdrawal from markets reduces potential growth |
| Technological Advances |
Improved diagnostics and devices favor newer drugs |
| Patent Status |
No current patent protections; off-patent status inhibits R&D investment |
Market Projection & Future Outlook
Short-term Outlook (1-3 Years)
| Projection |
Rationale |
| Continued limited clinical activity |
Existing safety concerns, no ongoing large trials |
| Potential niche use |
Off-label management in specific cases in some countries |
| Market decline |
Major markets have deprioritized use |
Long-term Outlook (4-10 Years)
| Projection |
Rationale |
| Negligible market presence |
Safer and more effective alternatives dominate |
| Rare research interest |
Scientific curiosity, but little financial incentive |
Revenue & Market Size Estimation
| Year |
Estimated Market Size |
Assumptions |
| 2023 |
<$10 million globally |
Based on historical prescriptions, scattered niche use |
| 2028 |
Near zero |
Market discontinuity, replaced by newer agents |
Potential for Revived Use
- Limited, primarily driven by emerging data on niche benefits or formulation advancements.
- Requires addressing safety issues and demonstrating clear advantages over existing therapies.
Comparative Overview: Marketed Antiarrhythmics
| Drug |
Class |
Safety Profile |
Market Status |
Approximate Market Size (2022) |
Comments |
| Amiodarone |
Class III |
Good efficacy but significant toxicity |
Large |
$700 million |
Gold standard; side effects limit use |
| Sotalol |
Class III |
QT prolongation risk |
Moderate |
$200 million |
Widely used |
| Mexiletine |
Class IB |
Good for specific indications |
Moderate |
$50 million |
Niche status |
| Moricizine |
Class I |
Safety concerns |
Deprecated |
< $10 million |
Limited current relevance |
Strategic Implications for Stakeholders
| Stakeholder |
Actionable Insights |
| Pharmaceutical Developers |
Focus on innovative antiarrhythmic agents with improved safety profiles; R&D in drug delivery or combination therapies rather than Moricizine redevelopment |
| Investors |
Limited investment potential in Moricizine-specific assets; consider related early-stage arrhythmia treatment technologies |
| Regulators |
Emphasize safety monitoring, especially for older drugs with historical issues |
| Clinicians |
Prefer newer, well-tolerated alternatives; limited role for Moricizine in current practice |
FAQs
1. Is Moricizine hydrochloride approved for use in any country today?
No; most jurisdictions have withdrawn or ceased approvals owing to safety concerns, especially related to proarrhythmia risk.
2. Are there ongoing clinical trials for Moricizine hydrochloride?
Currently, no active or recruiting Phase III trials are registered. Past trials have been concluded with limited continued development.
3. Can Moricizine hydrochloride be repurposed for any new indications?
Limited prospects exist; its safety profile constrains broader applications. Niche research in specific arrhythmia subsets or formulations could be explored but faces significant hurdles.
4. How does Moricizine compare to other antiarrhythmic drugs?
It shares similar efficacy to older agents like quinidine but has a worse safety profile, notably QT prolongation and proarrhythmic risk, leading to its obsolescence.
5. What are the main drivers that affected Moricizine’s market decline?
Safety issues, availability of better tolerated alternatives, regulatory withdrawals, and limited clinical efficacy data contributed to market exit.
Key Takeaways
- Clinical development of Moricizine hydrochloride has halted due to safety concerns, notably proarrhythmic risks.
- Market presence is minimal, with negligible revenues and no active regulatory approvals.
- The global antiarrhythmic market is dominated by newer agents with improved safety and efficacy profiles.
- Future prospects for Moricizine are limited; no significant pipeline or reformulation efforts are evident.
- Stakeholders should focus on innovative therapies and smarter risk management rather than re-evaluating Moricizine.
References
- FDA Drug Approvals & Withdrawals [1]
- ClinicalTrials.gov Database [2]
- Pharmacovigilance Reports (EMA, 2018) [3]
- Market Reports (IQVIA, 2022) [4]
Note: Data reflects publicly available information up to Q4 2022; ongoing developments may alter outlooks.
